Business context and reporting period
This is Tokai Pharmaceuticals, Inc.’s Form 10-K for the fiscal year ended December 31, 2016, filed March 3, 2017. The filing is not for Eledon Pharmaceuticals; the supplied company metadata does not match the registrant. The filing reports annual results, with selected fourth-quarter data, rather than a standalone Q4 report.
Tokai was a clinical-stage biopharmaceutical company with no product revenue. Its lead candidate, galeterone, was being developed for prostate cancer; its other program was early-stage androgen receptor degradation agents (ARDA).
Financial results and liquidity
| Metric | FY 2016 | FY 2015 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $25.0 million | $32.6 million |
| General and administrative expense | $13.1 million | $12.6 million |
| Total operating expenses | $38.1 million | $45.3 million |
| Net loss | $38.0 million | $45.1 million |
| Net loss per share | $1.68 | $2.01 |
| Cash used in operating activities | $36.5 million | $41.2 million |
Net loss narrowed by $7.1 million year over year, mainly as R&D expense fell $7.6 million following the ARMOR3-SV trial’s discontinuation. Lower clinical-trial, diagnostic-assay and manufacturing costs drove the R&D reduction; G&A rose $0.5 million, primarily due to severance. The company recorded $1.0 million of workforce-reduction costs and a $0.2 million impairment charge related to ARMOR3-SV assets. Operating and net margins are not meaningful because there was no revenue.
At December 31, 2016, cash and cash equivalents were $23.2 million and marketable securities were $4.2 million, for cash and investments of $27.4 million. Working capital was $26.7 million; total assets were $29.8 million, total liabilities $2.9 million, and stockholders’ equity $26.9 million. No borrowings or debt balance is reported. Cash used in operations was partly offset by $35.7 million of investing cash flow, principally maturities of marketable securities; financing cash flow was $0.04 million.
Management estimated that, assuming no new clinical efforts and no Otic transaction, year-end cash and investments would fund operations through at least the first quarter of 2018. Further development of galeterone or ARDA would require substantial additional funding. The filing reports no product-sales revenue and no cash dividends.
Material changes and developments
- In July 2016, an independent data monitoring committee concluded ARMOR3-SV was unlikely to meet its primary endpoint of improved radiographic progression-free survival versus enzalutamide in AR-V7-positive patients. The committee cited no safety concern; Tokai announced the trial’s discontinuation.
- Tokai also closed enrollment in the ARMOR2 expansion study and dropped a planned study in patients progressing rapidly on enzalutamide or abiraterone. Ten ARMOR2 patients remained on treatment as of January 31, 2017.
- The company reduced its workforce by approximately 60% in 2016; it had eight full-time employees as of January 31, 2017. R&D expense declined from $32.6 million in 2015 to $25.0 million in 2016, after rising sharply in 2015 as ARMOR3-SV began.
- The board began a strategic-alternatives review. In December 2016 Tokai agreed to acquire all Otic Pharma shares in exchange for Tokai common stock. The agreement was amended and restated March 2, 2017 and extended the termination date to May 31, 2017. The transaction remained subject to closing conditions, including stockholder and Nasdaq approvals; it was not completed as of the filing.
Outlook, risks, contingencies and unusual items
Management had not settled on a development path for galeterone or ARDA. It stated a substantial likelihood that it would not pursue galeterone in AR-V7-positive mCRPC; if the Otic transaction closed, Tokai did not expect Otic to continue galeterone development. No quantitative earnings or revenue guidance was provided.
Under the Otic agreement, Otic shareholders were expected to receive up to approximately 36.9 million Tokai shares, potentially owning about 60% of the combined company (62% if Otic options and warrants were exercised). A related commitment contemplated up to $7.0 million of new capital: purchasers agreed to buy approximately $4.0 million of Tokai shares at $1.11 per share at transaction closing, with the remaining $3.0 million intended for Otic through warrant exercises. Specified termination circumstances could require Tokai to pay Otic a $1.0 million fee or Otic to pay Tokai $1.5 million. Tokai also expected to owe its strategic adviser $1.0 million upon closing.
Key risks include failure or delay of the Otic transaction, continued operating losses and need for capital if it does not close, uncertain prospects following the Phase 3 setback, reliance on third-party manufacturers and clinical-service providers, and limited galeterone patent protection (the company disclosed no patent specifically covering its chemical structure). Four securities class actions related to alleged statements about galeterone trials and the IPO were pending; Tokai said it could not estimate potential losses or ranges. An unfavorable outcome could materially affect results and cash flows.
Important facts for investors to verify
- Whether the Otic transaction and related financing closed, and the final share issuance, ownership dilution, and transaction costs.
- Current cash runway and financing requirements under the company’s actual post-transaction or standalone operating plan.
- What, if anything, was decided about galeterone, the remaining ARMOR2 patients, and the ARDA program.
- Developments and potential exposure in the securities lawsuits, for which the filing provides no estimable loss range.
- Whether reported cash and investments, working capital, and low liabilities remain comparable after subsequent transactions and operating expenditures.